TABLE 1.

LFF571 serum concentrations at each time point

Study day	Time (h)	na	Concn (μg/ml) (median [range])	No. (%) of concn below lower limit of quantification
1	Predose	43	0 (0–0.627)	42 (97.7)
	1 after dose	16	0 (0–1.58)	10 (62.5)
	2–3 after dose	41	1.13 (0–22.2)	13 (31.7)
	4–6 after dose	13	3.69 (0–7.60)	2 (15.4)
3	Predose	43	4.00 (0–41.6)	2 (4.7)
	1 after dose	18	3.65 (0–24.1)	2 (11.1)
	2–3 after dose	43	2.54 (0–41.7)	2 (4.7)
	4–6 after dose	15	3.17 (0–17.1)	1 (6.7)
8 or 9	Predose	24	2.48 (0–30.5)	1 (4.2)
10 or 11	Predose	17	1.97 (0–28.1)	2 (11.8)
	1 after dose	12	2.39 (0–26.3)	2 (16.7)
	2–3 after dose	13	2.14 (0–19.4)	1 (7.7)
	4–6 after dose	10	2.16 (0.566–18.1)	0
12 or 13	12–72 after dose	43	0 (0–11.9)	25 (58.1)

^an, number of subject profiles that had adequate concentration data for evaluation. One patient had detectable LFF571 at baseline. The value was near the lower limit of quantification and was confirmed by repeat testing.